DIA
ALXN

Denver Investment Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Denver Investment Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-10,933
Closed -$2.08M – 532
2015
Q4 		$2.08M Buy
+10,933
New +$1.91M 0.09% 204
2015
Q1 		– Sell
-27,763
Closed -$5.14M – 673
2014
Q4 		$5.14M Sell
27,763
-8,929
-24% -$1.65M 0.16% 146
2014
Q3 		$6.08M Buy
36,692
+24,318
+197% +$3.99M 0.2% 135
2014
Q2 		$1.93M Sell
12,374
-24,926
-67% -$3.94M 0.06% 305
2014
Q1 		$5.67M Hold
37,300
– – 0.17% 170
2013
Q4 		$4.96K Buy
+37,300
New +$4.48M 0.14% 192

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Denver Investment Advisors's ALXN Position: Q1 2016 in Review

Denver Investment Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2016, closing a stake of 10,933 shares — an estimated $2.08M sold.

Denver Investment Advisors first reported a position in ALXN in Q4 2013 and held it in 6 quarters. The position peaked at $6.08M in Q3 2014. 518 funds tracked by Wall St. Rank hold ALXN as of Q1 2016.

  • Denver Investment Advisors reported no remaining Alexion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Denver Investment Advisors sold 10,933 Alexion Pharmaceuticals shares in Q1 2016, an estimated $2.08M.
  • Denver Investment Advisors first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 6 quarters.
  • Denver Investment Advisors's Alexion Pharmaceuticals position peaked at $6.08M in Q3 2014.
  • 518 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2016.

Based on Denver Investment Advisors's 13F filing for Q1 2016, filed 12 May 2016.